Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and Sequencing
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
In this video, Dr. Joyce O’Shaughnessy discusses the treatment landscape for patients who progress on ET + CDK4/6 inhibitors, including the importance of biomarker testing in this setting.
To access additional videos and download free resources, click here.
VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.
